Redeye is optimistic about the success of the safety cohort review.
Hansa adds positive 6m initial safety and early signs of efficacy in from the phase 2 GBS trial.
Redeye comments on FlexQube’s breakthrough order for its first autonomous robot (AMR), the Navigator...
Redeye provides the following initial take on Neonode's automotive contract announced earlier today.
Nya finansiella mål presenterade med fokus på tillväxt.
Redeye comments on the cost reduction program at IGM Biosciences which impacts birinapant, which is ...
Huddlestock Fintech AS (”Huddlestock” or the ”Company”) has demonstrated a high business pace during...
Redeye comments on the result of Active Biotech's rights issue.
Positive sales update for Q4 Oct-Nov sales of 25.2m (ABGSCe Q4 SEK 24) Implied upside of 13% to our ...
Redeye endorses the recent news that Herantis has completed a directed issue of EUR4.
Redeye initiates coverage of Iconovo, a Swedish medtech company specialising in developing inhalatio...
Rörelseintäkterna uppgick till 1,64 MSEK (0,99) i kvartalet, vilket var en ökning med 65,6 procent y...
AcuCort AB (”AcuCort” eller ”Bolaget”) har nyligen presenterat sin Q3-rapport och dessförinnan avslu...
Hanza förvärvar en kvalitativ kontraktstillverkare och stärker sina tillverkningskluster i Sverige o...
Redeye believes Integrum has good prospects of continuing to deliver positive EBIT during its high s...
Redeye provides an update following Strax Q2-results wich saw weak topline, higher costs and no news...
Redeye updates its estimates following Ngenic’s Q3 report, which presented the highest revenue ever ...
Redeye returns with an updated view of Saniona following the Q3 report and recent milestones in the ...
While the numbers for Q3’23 came in as expected, the key takeaways from the report conference call p...
Redeye provides a short research update following the positive phase Ib results with lead candidate ...